STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sutro Biopharma Inc (STRO) is not a strong buy at this moment for a beginner investor with a long-term focus. While the technical indicators suggest bullish momentum, the stock is currently overbought, and there are no strong proprietary trading signals or recent positive news catalysts to support immediate action. Additionally, the financial performance, while showing improvement, still reflects significant net losses. It would be prudent to monitor the stock for a better entry point or further positive developments.
The technical indicators for STRO show bullish momentum with the MACD histogram at 0.346 (positively expanding), RSI at 86.058 (indicating overbought conditions), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The current price of $24.01 is near the resistance level of R2: $24.79, suggesting limited immediate upside potential.
Analysts have upgraded the stock recently, with Citizens upgrading to Outperform and Deutsche Bank raising the price target to $
The company's STRO-004 entering the clinic and its dual payload antibody-drug conjugates expected to emerge in 2026 highlight potential long-term growth opportunities.
The stock is currently overbought based on RSI, suggesting a potential pullback.
No recent news or significant insider/hedge fund trading activity to support immediate bullish sentiment.
The financials, while improving, still reflect significant net losses and negative EPS.
In Q3 2025, revenue increased by 13.77% YoY to $9.69M, net income improved by 16.54% YoY but remains negative at -$56.86M, and EPS increased by 12.61% YoY to -6.7. Gross margin remains at 100%. While these metrics show improvement, the company is still operating at a loss.
Analysts are optimistic about the stock's long-term potential. Citizens upgraded the stock to Outperform with a $23 price target, citing its platform and cash per share value. Deutsche Bank raised the price target to $51, highlighting the potential of STRO-004 and the company's dual payload antibody-drug conjugates.
